ArticleFrontiers in cellular and infection microbiology2025
The diagnostic value of third-generation nanopore sequencing in non-tuberculous mycobacterial infections.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Oxford Nanopore Sequencing, a Promising Technology for Precision Diagnostics in Intensive Care Units: A Narrative Review.Biomedicines · 2026Review
- Nanopore Sequencing in Mycobacterial Diagnostics: Clinical and Laboratory Roles of mNGS and tNGS.Diagnostics (Basel, Switzerland) · 2026Review
- Zoonotic Nontuberculous Mycobacteria: Transmission Pathways, Laboratory Diagnosis, Detection Methodologies, and One Health Priorities.Infectious diseases & clinical microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the diagnostic value of nanopore sequencing technology in non-tuberculous mycobacterial pulmonary disease (NTMPD) and compare it with traditional culture methods. Methods: A retrospective analysis was conducted on 225 suspected NTMPD patients admitted to the Fourth People's Hospital of Nanning City from January 2022 to July 2024. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), kappa coefficient, and area under the receiver operating characteristic curve (AUC) of nanopore sequencing, culture, and combined diagnostic methods were compared to evaluate their diagnostic performance. In addition, patients were divided into different groups to investigate the detection of NTMPD by nanopore sequencing technology under different pathogen concentrations, in cases of concurrent Mycobacterium tuberculosis (MTB) infection, and among the elderly (aged > 60 years). Results: Among 139 NTMPD samples, nanopore sequencing detected positives in 113 cases, with a sensitivity of 81.3%, PPV of 99.1%, NPV of 76.6%, kappa coefficient of 0.759, and AUC of 0.901, demonstrating high specificity (98.8%) comparable to culture. The combined diagnostic approach significantly improved the sensitivity (90.6%), NPV (98.4%), kappa coefficient (0.862), and AUC (0.942) of NTMPD diagnosis. Nanopore sequencing showed superior diagnostic value in samples with various bacterial concentrations and in cases of concurrent MTB infection. Conclusion: Third-generation nanopore sequencing technology serves as a rapid and effective diagnostic tool, which may profoundly impact the current diagnosis of NTMPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.